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Available online 15 July 2017Bone loss is a serious clinical issue in patients with cerebral palsy (CP). Sclerostin has garnered interest as a key
mechanosensor in osteocytes, leading to considerations of the therapeutic utilization of anti-sclerostin medica-
tions. This study was undertaken to determine associations among mechanical unloading, sclerostin levels, and
bone imbalance in patients with CP. A total of 28 patients with CP participated in this cross-sectional study.
The following measurements were taken: anthropometrics, clinical diagnosis of CP subtype and ambulatory sta-
tus, bonemineral density (BMD) z-scores at the lumbar spine and hip, and blood biochemicalmarkers, including
sclerostin, parathyroid hormone (PTH), osteocalcin, C-terminal telopeptide, 25-hydroxyvitamin D, 1,25-
dihydroxyvitamin D, creatinine, calcium, and phosphorus. In analysis according to CP subtype, patients with
spastic CP showed signiﬁcantly lower BMD z-scores at the lumbar spine and femur neck regions than patients
with dyskinetic CP. In analysis according to ambulatory status, patients with non-ambulatory CP showed signif-
icantly lower BMD z-scores at all lumbar spine and femoral sites, lower PTH and creatinine levels, and higher
plasma sclerostin levels than patients with ambulatory CP. In regression analysis, ambulatory status was a signif-
icant determinant of plasma sclerostin levels. This study is the ﬁrst to report on sclerostin levels and BMD in pa-
tients with CP, based on the hypothesis that patients who lack sufﬁcient weight-bearing activities would show
increased sclerostin levels and decreased BMD scores, compared with patients who sustain relatively sufﬁcient
physical activity. Therefore, this report may provide clinical insights for clinicians considering ambulatory status,
sclerostin levels, and bone loss in patients with CP.ral dens
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Cerebral palsy (CP) from neonatal brain events results in a profound
loss of bone balance due to prolonged conditions of paralysis and limit-
ed weight bearing in adulthood. Dysregulated muscle tone and posture
following brain disturbance interfere with normal movement and bone
health [1,2]. Bone loss in adulthood CP increases not only the risk of frac-
ture but also the risk of medical complications [3,4]. Despite theseity; PTH, parathyroid
ELISA, enzyme-linked
, radioimmunoassay;
tute of Rehabilitation
ublic of Korea.
o this study.
n open access article underserious problems, there is no standard treatment for bone loss in pa-
tients with CP.
Recently, sclerostin has garnered more interest than any other bio-
logical markers of bone. Sclerostin has newly been identiﬁed as a key
molecule in osteocytes: it acts as a mechanosensor regulating bone bal-
ance in response to weight loading under gravity [5–8]. Sclerostin po-
tently inhibits bone formation by competing with Wnt and LRP5 or
LRP6 receptor signaling cascades, which are related to osteogenesis, in
vivo and in vitro. In these molecular pathways, sclerostin inhibits oste-
oblast differentiation and proliferation, ultimately resulting in bone
loss [5–7,9–11].
Several reports have shown that sclerostin levels change in response
to partial or complete mechanical unloading in human subjects [8,12–
14]. Gaudio et al. [8] revealed that higher sclerostin levels were nega-
tively associatedwith bone formationmarkers and positively associated
with bone resorption markers in patients who were immobilized inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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levels increased in response to prolonged skeletal disuse for 90 days in
healthy adults. The increase in serum sclerostin was accompanied by a
decrease in serum PTH, increase in urinary bone resorption marker
and calcium, and decrease in bone mineral density (BMD). Power et
al. [14] showed that osteocyte sclerostin was inversely correlated with
the bone formation marker alkaline phosphatase in musculoskeletal
diseases, such as osteoarthritis and femur neck fracture. Morse et al.
[15] found that circulating sclerostin levels were lower in patients
with complete spinal cord injury who required the use of wheelchair
than in patients with incomplete injury who did not require the use of
wheelchair. These previous studies suggest that the association be-
tween sclerostin and bone imbalance is stronger in severe disease con-
ditions that interfere with normal weight bearing through the lower
extremities.
To date, few studies have taken into account sclerostin activity in re-
sponse tomechanical loadingwhen analyzing bone loss following brain
injury. Our study aimed to elucidate the associations amongmechanical
unloading, sclerostin level, and bone imbalance in patients with CP. Sig-
niﬁcant bone loss has been found in patients with spastic CP and pa-
tients with non-ambulatory CP due to their limited movement [2,16,
17]. Our cross-sectional study was undertaken to compare bone meta-
bolic changes and BMD differences across two parameters (CP subtype
and ambulatory status) and to investigate the role of sclerostin in pa-
tients with CP. With this rationale, we hypothesized that patients with
spastic CP and patients with non-ambulatory CP would show higher
sclerostin levels and lower BMD, in favor of bone resorption, than pa-
tients with dyskinetic CP and patients with ambulatory CP.
2. Materials and methods
2.1. Participants
This studywas designed as a cross-sectional study. All subjects visit-
ed our institution for concerns regarding osteoporosis or treatment for
low BMD. After screening, subjects who were not eligible in our study
were excluded in accordance with the following criteria: (1) age
under 20 years; (2) history of drug or medication use that could affect
bone metabolism within the previous 12 months, such as bisphospho-
nate, anticonvulsants, and glucocorticoid; (3) any diseases that might
affect bone metabolism, such as diabetes, hyperparathyroidism,
hypercortisolism, rheumatoid arthritis, and bone tumor; and (4) sys-
temic illness, such as kidney, liver, and thyroid diseases. Ultimately, 28
patients were determined to be eligible for our study. A healthy control
group of 18 age-matched subjects were also recruited. The demograph-
ical characteristics of the healthy controls are provided as follows: me-
dian age (31.50 years), height (165.50 cm), weight (58.50 kg), and
body mass index (BMI) (21.09 kg/m2).
This research was carried out with human subjects by complying
with theDeclaration of Helsinki. This studywas approved by the Institu-
tional Review Board (4-2013-0404) of Yonsei University Health System.
Informed consent was obtained from all participants, who approved all
procedures of this study.
2.2. Clinical categories of patients with cerebral palsy
All participants were placed into two clinical categories according to
subtype of cerebral palsy and ambulatory status. Regarding CP subtype,
a participant who showed impairment of joint mobility due to hyper-
tonic muscle was categorized as spastic CP. A participant who showed
repetitive involuntary movement due to mixed hypo- and hyper-tonic-
ity was categorized as dyskinetic CP. Regarding ambulatory status, a
participant who was able to walk independently or with crutches and
walkers was categorized as ambulatory CP. A participant who was
able to move around via a wheelchair was categorized as non-ambula-
tory CP.2.3. Measurement of biochemical markers
Participants were asked to fast 8 h prior to blood sampling. Blood
samples were obtained via venous puncture and analyzed according
to the institutional standard guidelines as follows: (1) serum parathy-
roid hormone (PTH) was measured by immunoradiometric assay
(IRMA) using commercial kits (Biosource, Nivelles, Belgium); (2)
serum osteocalcin (OCN) concentrations were measured by an en-
zyme-linked immunosorbent assay (ELISA) (CIS Bio International, Gif-
sur-Yvette, France); (3) serum C-telopeptide of type I collagen (CTx)
concentrationsweremeasured by ELISA (Osteomark, Ostex Internation-
al, Seattle, WA, USA); (4) serum 25-hydroxyvitamin D (25(OH)D) and
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) were measured by radioim-
munoassay (RIA) using commercial kits (D or D3-RIA-CT, Biosource, Ni-
velles, Belgium); (5) serum calcium and phosphate were measured by
standard routine chemistry techniques using an automatic device
(Hitachi, Tokyo, Japan); and (6) serum creatinine was also measured
by a standard routine chemistry technique using an automated chemis-
try analyzer (Hitachi, Tokyo, Japan) to identify renal function in all
participants.
2.4. Measurement of plasma sclerostin concentrations
Peripheral blood sampleswere obtained from each participant. After
centrifuging whole blood for 10 min at 2000–2500 g, the supernatants
were collected. All plasma sampleswere immediately frozen and stored
at−80 °C before ELISA, a method to determine sclerostin concentra-
tions. Plasma sclerostin levels were determined using an
immunoperoxidase assay kit (E-80SST, Immunology Consultants Labo-
ratory Inc., Portland, USA) following the manufacturer's instructions
(http://www.icllab.com/human-sclerostin-elisa-kit.html). Individual
sclerostin concentration results were obtained by calculating the
mean value from sample duplication.
2.5. Measurement of bone mineral density
The BMD was measured at the lumbar spine (L1-L4), proximal
femur (femoral neck, intertrochanter), and total femur by dual-energy
x-ray absorptiometry (Delphi A, Hologic,Waltham,MA, USA) with soft-
ware version 12.6.
2.6. Statistics
All statistical analyses were performed with SPSS Statistics 23 (IBM
Corp., Armonk, NY, USA). Median and interquartile ranges (25th–75th
percentiles) were used for non-normally distributed variables, and p b
0.05 was considered statistically signiﬁcant. Chi-square test was used
to identify differences in sex distribution between groups. Mann-Whit-
ney U tests were used to compare the difference between two groups in
regards to demographic parameters, biochemical markers, and BMD.
Regression analysis was used to identify relationships betweenmultiple
variables and sclerostin and to investigate predictive variables of
sclerostin concentration.
3. Results
3.1. Comparison according to subtype of CP
The clinical characteristics of our subjects are shown in Table 1 and
Table 2. Twenty-eight patients diagnosed with CP (median age,
38.00 years) participated in this study. Baseline characteristics are
shown according to two clinical criteria, namely CP subtype and ambu-
latory status. Sixteen patients with spastic CP and 12 patients with dys-
kinetic CP participated in this study (Table 1). There were no signiﬁcant
differences in demographic parameters, such as age, sex, and BMI, blood
biochemistry markers, or plasma sclerostin levels between groups.
Table 1
Baseline characteristics of participants according to subtype of cerebral palsy.
Parameter Normal range Spastic CP
(n= 16)
Dyskinetic CP
(n= 12)
p-value
Age (years) – 26.00 (21.25–44.50) 42.00 (36.25–46.00) 0.063
Sex (M/F) – 8/8 7/5 0.662
BMI (kg/m2) 18.5–25 22.57 (18.47–24.38) 22.14 (19.95–24.52) 0.745
Sclerostin concentration (pg/mL) – 347.83 (250.54–418.70) 256.39 (185.17–369.38) 0.137
PTH (pg/mL) 15–65 39.00 (29.83–48.50) 46.50 (35.53–60.53) 0.114
OCN (ng/mL) 14–42 28.29 (20.90–31.88) 19.56 (14.55–25.59) 0.084
CTx (ng/mL) 0.584 0.52 (0.33–0.77) 0.30 (0.22–0.51) 0.093
25-hydroxyvitamin D (ng/mL) Deﬁciency b9
Insufﬁciency 10–29
Sufﬁciency 30–100
12.54 (10.59–23.10) 12.44 (8.98–17.60) 0.676
1,25-dihydroxyvitamin D3 (pg/mL) 19.6–54.3 39.85 (28.95–59.78) 37.85 (22.20–49.63) 0.430
Creatinine (mg/dL) 0.49–0.91 0.62 (0.51–0.71) 0.69 (0.61–0.73) 0.178
Calcium (mg/dL) 8.5–10.5 9.30 (9.00–9.58) 9.10 (8.70–9.50) 0.359
Phosphorus (mg/dL) 2.5–4.5 3.90 (3.58–4.10) 3.50 (3.40–3.90) 0.119
Note.Median (interquartile range); *p b 0.05; BMI: body mass index; PTH: parathyroid hormone; OCN: osteocalcin; CTx: C-telopeptide of type I collagen.
Table 2
Baseline characteristics of participants according to ambulatory status.
Parameter Normal range Ambulatory CP
(n= 13)
Non-ambulatory CP
(n= 15)
p-value
Age (years) – 36.00 (23.50–43.00) 39.00 (24.00–48.00) 0.489
Sex (M/F) – 8/5 7/8 0.431
BMI (kg/m2) 18.5–25 23.53 (20.14–24.81) 20.00 (18.02–24.22) 0.123
Sclerostin concentration (pg/mL) – 237.71 (195.50–295.59) 390.68 (328.46–457.61)* 0.008
PTH (pg/mL) 15–65 50.60 (36.15–62.80) 37.70 (30.70–45.40)* 0.023
OCN (ng/mL) 14–42 23.51 (15.49–32.22) 25.59 (18.69–30.57) 0.661
CTx (ng/mL) 0.584 0.47 (0.24–0.55) 0.44 (0.27–0.75) 0.961
25-hydroxyvitamin D (ng/mL) Deﬁciency b 9
Insufﬁciency 10–29
Sufﬁciency 30–100
10.65 (8.33–14.87) 17.95 (10.70–23.12) 0.062
1,25-dihydroxyvitamin D3 (pg/mL) 19.6–54.3 37.90 (25.80–44.60) 45.10 (27.30–61.30) 0.381
Creatinine (mg/dL) 0.49–0.91 0.70 (0.66–0.75) 0.57 (0.46–0.69)* 0.005
Calcium (mg/dL) 8.5–10.5 9.15 (8.73–9.50) 9.30 (9.00–9.60) 0.448
Phosphorus (mg/dL) 2.5–4.5 3.70 (3.33–3.98) 3.90 (3.50–4.10) 0.240
Note. Median (interquartile range); *p b 0.05; BMI: body mass index; PTH: parathyroid hormone; OCN: osteocalcin; CTx: C-telopeptide of type I collagen.
Table 3
Linear regression analysis for predicting sclerostin levels from clinical variables.
Model Univariate analysis Multivariate analysis
Variables (reference) Coefﬁcient (SE) p-value Coefﬁcient (SE) p-Value
Age 0.51 (2.37) 0.832 −0.48 (2.40) 0.842
Sex (male) 35.91 (49.84) 0.478 21.21 (50.56) 0.679
BMI −1.81 (7.15) 0.802 3.20 (7.09) 0.656
Ambulatory status (ambulatory) 117.54 (44.75) 0.014 121.57 (49.94) 0.023
Subtype of CP (spastic) −61.44 (49.28) 0.224 – –
PTH −1.78 (1.39) 0.211 – –
OCN 1.47 (3.26) 0.657 – –
CTx −47.90 (99.46) 0.634 – –
25-hydroxyvitamin D 0.83 (3.60) 0.820 – –
Creatinine −81.88 (205.42) 0.693 – –
Calcium 63.65 (60.49) 0.303 – –
Phosphorus −8.45 (48.10) 0.862 – –
Note. *p b 0.05; SE (standard error); BMI: body mass index; PTH: parathyroid hormone;
OCN: osteocalcin; CTx: C-telopeptide of type I collagen. Linear regression analysiswas con-
ducted to identify signiﬁcant variables affecting sclerostin levels in patients with cerebral
palsy. The ﬁnalmodel revealed a signiﬁcant association between sclerostin and ambulato-
ry status, which was signiﬁcant in the univariate model, after adjustment for demograph-
ical factors, including age, sex, and BMI.
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Thirteen patients with ambulatory CP and 15 patients with non-am-
bulatory CP participated in this study (Table 2). There were no signiﬁ-
cant differences in demographic parameters. In the analysis of blood
biochemistry markers, there were no signiﬁcant differences in OCN,
CTx, 25(OH)D, 1,25(OH)2D3, calcium, or phosphorus between groups.
However, patients with non-ambulatory CP had lower PTH (37.70 vs.
50.60 pg/mL) and creatinine (0.57 vs. 0.70 mg/dL) levels than patients
with ambulatory CP. Furthermore, patients with non-ambulatory CP
showed higher sclerostin levels (390.68 vs. 237.71 pg/mL) than patients
with ambulatory CP.
3.3. Association between ambulatory status and sclerostin levels
Linear regression analysis was conducted to identify signiﬁcant var-
iables affecting sclerostin levels in patients with CP. The ﬁnal model re-
vealed a signiﬁcant association between sclerostin and ambulatory
status (p = 0.023), which was signiﬁcant in the univariate model
(p = 0.014), after adjustment for demographical factors, including
age, sex, and BMI (Table 3).
3.4. Comparison of BMD in ambulatory status and CP subtype
In comparison of bone densities between different CP types, the
spastic CP group had signiﬁcantly lower BMD z-scores for the lumbarspine (−1.60 vs. – 0.80) and femur neck (−1.75 vs.−0.55) than the
dyskinetic CP group (Fig. 1-A).
Comparing bone densities between ambulatory/non-ambulatory
groups, results showed that patients with non-ambulatory CP had sig-
niﬁcantly lower BMD z-scores than patients with ambulatory CPwithin
Fig. 1.Group comparison of lumbar and femur bonemineral density scores according to subtype of CP (A) and ambulatory status (B). Bonemineral density (BMD) z-scores in the lumbar spine and femur neckwere signiﬁcantly lower in patients with
spastic CP, compared to patients with dyskinetic CP (A. a&c). All BMD levels were signiﬁcantly lower in patients with non-ambulatory CP than in patients with ambulatory CP (B. a-d). Statistical analysis was performed using Mann-Whitney U test.
Median (interquartile range); *p b 0.05.
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306 Y.-K. Shin et al. / Bone 103 (2017) 302–307regions of the lumbar spine (−1.80 vs.−0.80), femur neck (−1.80 vs.
−0.50), femur inter-trochanter (−2.60 vs. −1.20), and total hip
(−2.00 vs.−0.90) (Fig. 1-B).
4. Discussion
In the present study, we discovered that patients with non-ambula-
tory CP show signiﬁcantly higher circulating levels of sclerostin than pa-
tients with ambulatory CP. Further, plasma sclerostin concentrations
were found to be correlated with ambulatory status in regression anal-
ysis. Theseﬁndings suggest that themain contributing factor to circulat-
ing sclerostin is the mechanical stimulation of habitual weight bearing
in adults with CP. Furthermore, BMD levels of the lumbar spine and
hip were lower in patients with non-ambulatory CP than patients
with ambulatory CP. These results lend support to our hypothesis that
patients who have limited weight bearing due to a wheelchair-depen-
dent life would show higher sclerostin levels and lower BMD than pa-
tients who sustain relatively sufﬁcient physical activity.
We also found that patients with CP show signiﬁcantly lower circu-
lating sclerostin levels than healthy controls (p b 0.01; 309.83 vs.
532.42), in linewith theprevious report [15].Morse et al., however, sug-
gested that lower sclerostin levels in chronic patientswith complete pa-
ralysis were due to a greater loss of osteocytes in an acute stage,
compared to patients with incomplete paralysis. In other words, the
greater loss of osteocyte numbers following severe bone loss could
lead to lower sclerostin levels under the extreme osteoporosis condition
in spinal cord injured patients with complete paralysis. We speculate
that these discrepancies might stem from etiological heterogeneity be-
tween the different cohorts. In our study, patients with non-ambulatory
CP were not in completely paralyzed conditions unlike complete spinal
cord injury. Therefore, we suspect the difference in the numbers of oste-
ocyte between subgroups based on injury severity was less than in spi-
nal cord injured patients. Taken together, osteocytes might be similar
in patients with CP regardless of ambulatory status, and the number
thereof might differ only between normal controls and patients
with CP. Therefore, we suggest that differences in mechanical load-
ing between subgroups in CP might signiﬁcantly affect sclerostin
levels, in line with the previous report in chronic patients with
stroke [8].
While sclerostin levels were not sensitive to CP subtype, we found
that patients with spastic CP, who suffer from hypertonicity and limited
joint movement, showed lower BMD in the lumbar spine and femoral
neck than patients with dyskinetic CP, who suffer from mixed muscle
tones and hyperkinetic patterns. Although it was not statistically signif-
icant, the patterns of bone resorption markers in the participants in our
study were consistent with previous data. Speciﬁcally, a previous study
showed that adultswith non-ambulatory spastic CP had lower BMDand
higher concentrations of the bone resorption marker CTx than patients
with ambulatory spastic CP and patients with dyskinetic CP. This result
suggests that reducedweight loading and jointmobility in patientswith
CP can contribute to the imbalance in bone metabolism [2].
Adults with CP commonly have musculoskeletal abnormalities, in-
cluding osteopenia or osteoporosis at an early age [16,18]. Although
there is insufﬁcient information about BMD and other contributing fac-
tors in adults with CP, several studies have shown an association be-
tween BMD and certain risk factors [4,19,20]. Previous studies have
commonly revealed that functional decline has a strong association
with BMD in adults with CP. Altogether, these results imply that ambu-
latory function contributes to the microenvironment for bone health in
patients with CP.
In the bone microenvironment, sclerostin is nearly exclusively se-
creted by osteocytes and could exert a negative osteogenic effect by
inhibiting Wnt-signaling under the condition of reduced mechanical
loading. Moustafa et al. [21] showed that axially applied mechanical
loading is associated with decreased sclerostin levels and increased
new bone formation in the proximal tibia and secondary spongiosa inmice. However, these osteogenic effects were reversed by sciatic
neuroectomy-induced disuse. Robling et al. [6] showed that artiﬁcially
enhanced mechanical stimulation reduced SOST gene transcripts
and sclerostin protein expression, especially in the high compression
regions of the murine bone. These evidences suggest that sclerostin
has a key role in the regulation of mechanotransduction and support
the therapeutic concept of anti-sclerostin intervention in patients with
CP.
An interesting ﬁnding of this study was that low serum creatinine
levels were found in patients with reduced BMD, consistentwith the re-
cent study [22]. Huh et al. demonstrated that subjects who had low
serum creatinine showed low bone density, presumably because of
cross-talk between bone and muscle. In a parallel fashion, patients
with non-ambulatory CP showed lower serumcreatinine levels than pa-
tients with ambulatory CP, and this resultmight be related tomuscle at-
rophy caused by limitation of physical activity [23].We propose that the
deleterious effects of CP on BMD primarily reﬂect a lack of physical ac-
tivity and associated sclerostin response to limited mechanical loading
caused by a lifelongmotor deﬁcit in adults with CP. Therefore, clinicians
need to consider both exercise and anti-sclerostin treatments as a syn-
ergistic strategy to enhance the anabolic effects on bone in patients
with CP [13,24–29].
This is a cross-sectional study. Longitudinal measures of sclerostin
levels, BMD, and other clinical factors would be informative toward un-
derstanding the cumulative effects of weight bearing on sclerostin
levels with aging in patients with CP. A larger sample sizewould be nec-
essary to better investigate the relationships between sclerostin levels
and bone metabolism-related factors. Despite these limitations, this
study may provide clinical insights on sclerostin levels in response to
prolonged mechanical unloading under the pre-existing pathological
conditions found in patients with CP.
5. Conclusions
This study discloses a novel ﬁnding concerning bone health in adults
with CPwho showed differences in sclerostin and BMD levels according
to ambulatory status. Patients with non-ambulatory CP showed higher
sclerostin levels and lower lumbar spine and femur BMD than patients
with ambulatory CP. Ambulatory status was a signiﬁcant predictor of
sclerostin levels in patients with CP. This report may provide a clinical
insight for clinicians considering diagnosis and treatment for bone loss
in patients with CP.
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